1373038-57-3

Usage

Uses

Used in Pharmaceutical Industry:
C₁₆H₁₂ClNO₃S is used as an impurity in the manufacturing process of Parecoxib Sodium (P193275), a selective cyclooxygenase-2 (COX-2) inhibitor. Its presence is significant for quality control and ensuring the purity of the final drug product.
Used in Chemical Synthesis:
C₁₆H₁₂ClNO₃S is also used as a reagent for the synthesis of valdecoxib, another COX-2 inhibitor. Its unique functional groups make it a valuable component in the chemical reactions required to produce this pharmaceutical compound.

Upstream product

• 33512-94-6 m-nitrobenzhydroxamoyl chloride 
• 3431-62-7 3-nitrobenzaldoxime 
• 99-61-6 3-nitro-benzaldehyde 
• 37928-17-9 5-methyl-3,4-diphenyl isoxazole 
• 103-79-7 1-phenyl-acetone 
• 52201-28-2 1-(1-methyl-2-phenyl ethenyl)-pyrrolidine 
• 857259-65-5 5-methyl-3,4-diphenyl-5-(pyrrolidin-1-yl)-4,5-dihydroisoxazole 

Downstream Products

• 1373038-56-2 3-(5-methyl-4-phenylisoxazol-3-yl)benzenesulfonamide 

Relevant academic research and scientific papers

Synthesis method of parecoxib sodium isomeric impurities

The invention provides a synthesis method of parecoxib sodium isomeric impurities. Structures of the parecoxib sodium isomeric impurities are shown in formulae I and II in the description. The synthesis method comprises the following steps: the compound as shown in the formula I is subjected to reaction with the compound as shown in formula II or the compound as shown in formula III under the action of alkali, and a compound as shown in formula IV is generated; the corresponding parecoxib sodium isomeric impurities are generated by reduction reaction, diazotization, sulfonylation, amino substitution reaction and acylation reaction; the total reaction yield is higher than 22%, and purity of a target product is higher than 99%.

Directional preparation method and application of diaryl substituted isoxazole compound

The present invention discloses a parecoxib sodium impurity S, namely, N-{3-[(5-methyl-4-phenylisoxazol-3-yl)phenyl]sulfonyl}propionamide, and an preparation method thereof, and belongs to the technical field of chemical pharmacy. The method comprises the following steps: 5-methyl-3,4-diphenylisoxazole is used as a starting raw material, and the reaction conditions and an auxiliary reagent are controlled to increase the ratio of a sulfonyl chloride group connected to the meta-position of a phenyl ring at a 3-position of an isoxazole ring; and an amination reaction is performed, a crystallization mother liquid is concentrated to dryness, the obtained product is subjected to propionylation, and finally through preparative liquid chromatography separation, the parecoxib sodium impurity S is obtained. The high-purity parecoxib sodium impurity S provided by the present invention can be used as an impurity standard product in the detection and analysis of a finished product of parecoxib sodium, so that the accurate positioning and chemical composition determination of impurities in the detection and analysis of the finished product of the parecoxib sodium are promoted, reinforcement of control of the impurities is facilitated, and the quality of the finished product of the parecoxib sodium is further improved. The method provided by the invention has the advantages of cheap and easyraw materials, simple operation, good reproducibility, and an HPLC purity of 99.5% or more.

Application of [3+2]-cycloaddition in the synthesis of valdecoxib

A large scale synthesis of valdecoxib 1 is described. Our work features potential application of [3+2]-dipolar cycloaddition involving enamine and in situ-generated nitrile oxide derivatives. Dr. Reddy's Laboratories Ltd.